MIRA Financial Statements From 2010 to 2025

MIRA Stock   1.17  0.09  8.33%   
MIRA Pharmaceuticals, financial statements provide useful quarterly and yearly information to potential MIRA Pharmaceuticals, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on MIRA Pharmaceuticals, financial statements helps investors assess MIRA Pharmaceuticals,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting MIRA Pharmaceuticals,'s valuation are summarized below:
Market Capitalization
17.9 M
Earnings Share
(0.55)
We have found ninety-nine available fundamental ratios for MIRA Pharmaceuticals,, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of MIRA Pharmaceuticals, last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself next year. As of March 19, 2025, Enterprise Value is expected to decline to about 75.1 M
Check MIRA Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MIRA Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.3 M, Interest Expense of 4.2 M or Selling General Administrative of 7.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.21. MIRA financial statements analysis is a perfect complement when working with MIRA Pharmaceuticals, Valuation or Volatility modules.
  
Check out the analysis of MIRA Pharmaceuticals, Correlation against competitors.

MIRA Pharmaceuticals, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsM5.7 M1.3 M
Slightly volatile
Short and Long Term Debt Total4.3 K4.6 K111.8 K
Very volatile
Other Current Liabilities26.7 K16.6 KK
Slightly volatile
Total Current Liabilities855.9 K641.8 K344.6 K
Slightly volatile
Cash5.6 M5.3 M1.2 M
Slightly volatile
Non Current Assets Total81.1 K85.3 K82.6 K
Slightly volatile
Non Currrent Assets Other75.5 K79.5 K59.2 K
Slightly volatile
Cash And Short Term Investments5.6 M5.3 M1.2 M
Slightly volatile
Common Stock Shares Outstanding17.3 M21.4 M15.6 M
Slightly volatile
Liabilities And Stockholders EquityM5.7 M1.3 M
Slightly volatile
Other Stockholder Equity31 M29.5 M6.2 M
Slightly volatile
Total Liabilities879.1 K641.8 K351.3 K
Slightly volatile
Total Current Assets5.9 M5.6 M1.2 M
Slightly volatile
Short Term Debt4.3 K4.6 K106.5 K
Very volatile
Common Stock1.3 K1.3 K5.1 K
Slightly volatile
Accounts Payable592 K484.7 K739.6 K
Slightly volatile
Other Current Assets183 K294 K129.8 K
Slightly volatile
Short and Long Term Debt170.4 K119.8 K254.6 K
Slightly volatile
Capital Stock7.1 K7.7 K6.5 K
Slightly volatile
Property Plant Equipment290.9 K327.3 K356.9 K
Slightly volatile
Net Receivables9.5 K10.7 K11.6 K
Slightly volatile

MIRA Pharmaceuticals, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization10.3 M9.8 M1.9 M
Slightly volatile
Interest Expense4.2 MM727.7 K
Slightly volatile
Selling General Administrative7.8 M7.5 M1.7 M
Slightly volatile
Selling And Marketing Expenses278.5 K521.6 K171.4 K
Slightly volatile
Other Operating Expenses10.3 M9.8 M2.4 M
Slightly volatile
Research Development1.3 M1.8 M490.6 K
Slightly volatile
Total Operating Expenses10.3 M9.8 M2.4 M
Slightly volatile
Cost Of Revenue6.8 M7.7 M8.4 M
Slightly volatile

MIRA Pharmaceuticals, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow383404176.1 K
Pretty Stable
Total Cash From Financing Activities7.5 K7.9 K459.7 K
Slightly volatile
End Period Cash Flow3.9 K4.1 K200.7 K
Pretty Stable
Change To Netincome1.6 M1.5 M374.2 K
Slightly volatile
Change In Working Capital727765591.3 K
Slightly volatile
Issuance Of Capital Stock6.1 M10.7 M5.2 M
Slightly volatile
Depreciation585.8 K659.1 K718.6 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.00.00.0
Slightly volatile
Payables Turnover12.6614.2515.5341
Slightly volatile
Cash Per Share0.230.220.0572
Slightly volatile
Days Payables Outstanding18.4520.7522.6239
Slightly volatile
Income Quality0.660.430.6156
Pretty Stable
Current Ratio8.237.831.7632
Slightly volatile
Interest Debt Per Share0.180.170.0412
Slightly volatile
Debt To Assets0.00110.00122.2311
Slightly volatile
Days Of Payables Outstanding18.4520.7522.6239
Slightly volatile
Ebt Per Ebit0.891.261.0392
Slightly volatile
Effective Tax Rate0.00180.00110.0024
Slightly volatile
Quick Ratio8.237.831.7632
Slightly volatile
Cash Ratio7.797.421.6692
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9814
Slightly volatile
Debt Ratio0.00110.00122.2311
Slightly volatile

MIRA Pharmaceuticals, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap75.7 M85.2 M92.9 M
Slightly volatile
Enterprise Value75.1 M85.3 M92.8 M
Slightly volatile

MIRA Fundamental Market Drivers

Cash And Short Term Investments4.6 M

MIRA Upcoming Events

29th of December 2023
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View
30th of June 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About MIRA Pharmaceuticals, Financial Statements

MIRA Pharmaceuticals, stakeholders use historical fundamental indicators, such as MIRA Pharmaceuticals,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although MIRA Pharmaceuticals, investors may analyze each financial statement separately, they are all interrelated. For example, changes in MIRA Pharmaceuticals,'s assets and liabilities are reflected in the revenues and expenses on MIRA Pharmaceuticals,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MIRA Pharmaceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-17.6 K-18.5 K
Cost Of Revenue7.7 M6.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether MIRA Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MIRA Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mira Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mira Pharmaceuticals, Common Stock:
Check out the analysis of MIRA Pharmaceuticals, Correlation against competitors.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MIRA Pharmaceuticals,. If investors know MIRA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MIRA Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.55)
Return On Assets
(0.81)
Return On Equity
(1.92)
The market value of MIRA Pharmaceuticals, is measured differently than its book value, which is the value of MIRA that is recorded on the company's balance sheet. Investors also form their own opinion of MIRA Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is MIRA Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MIRA Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect MIRA Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MIRA Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if MIRA Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MIRA Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.